Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis IV: Nursing Management

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gut Commensal <i>Bacteroidetes</i> Encode a Novel Class of Vitamin B<sub>12</sub>-Binding Proteins.

mBio·2022

Same author

<i>De novo</i> synthesis of alkyne substituted tryptophans as chemical probes for protein profiling studies.

Organic chemistry frontiers : an international journal of organic chemistry·2017

Same author

Caveolae in ventricular myocytes are required for stretch-dependent conduction slowing.

Journal of molecular and cellular cardiology·2014

Same author

Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal.

Neurology·2008

Same author

Effect of a legislative mandate on mammography use and coding practices in Maryland.

Radiology·1996

Search research articles

Related Experiment Video

Updated: Jul 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Successful management of lipid-lowering programs.

Managed Care (Langhorne, Pa.)

|January 5, 2002

Summary

Demonstrating the value of health improvement programs requires presenting quantitative data to managed care organization (MCO) business professionals. This approach enhances program adoption by aligning with their financial expertise.

Area of Science:

Health Services Research
Managed Care Management
Health Economics

Background:

Managed care organizations (MCOs) face increasing pressure to justify health improvement program investments.
Business professionals in MCOs often lack clinical backgrounds, necessitating data-driven justifications.
Effective program advocacy requires understanding MCO decision-makers' financial priorities.

Purpose of the Study:

To outline a strategy for demonstrating the value of health improvement programs to MCO business professionals.
To emphasize the importance of using quantitative, financially relevant data for program advocacy.
To identify key characteristics of diseases/conditions suitable for intervention validation within MCOs.

Main Methods:

Analyzing the communication gap between health program advocates and MCO business professionals.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Related Experiment Videos

Last Updated: Jul 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Identifying the data preferences of MCO financial decision-makers.

Defining criteria for selecting diseases/conditions for program validation.

Main Results:

Quantitative, cost-effectiveness data are crucial for MCO business professional buy-in.
Programs addressing high-cost, high-volume conditions with practice variation are more likely to be validated.
Tailoring arguments to financial metrics significantly increases the probability of program implementation.

Conclusions:

Health improvement programs must adopt a business-oriented, data-driven approach for successful adoption in MCOs.
Presenting grounded, quantitative results is imperative for securing MCO investment.
Focusing on specific disease characteristics enhances the persuasive power of program proposals.